FDA Approves Dexycu Intraocular Suspension for the treatment of Postoperative Ocular Inflammation
Icon Bioscience receives FDA approval for Dexycu (dexamethasone intraocular suspension) for treating inflammation associated with Cataract Surgery
Company: Icon Bioscience Inc.
Brand Name: Dexycu
Generic Name: dexamethasone
Dosage Form: Intraocular Suspension
Treatment For: Postoperative Ocular Inflammation
General information about Dexycu
Dexycu (dexamethasone) is a long-acting, injectable corticosteroid formulation administered intraocularly into the posterior chamber of the eye for the treatment of postoperative inflammation associated with cataract surgery.
Dexycu delivers a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye via a single injection at the end of surgery, eliminating the burden of self-administering medicated eye drops several times a day in a primarily elderly patient population.